deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01850524

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Multiple Myeloma
Interventions Dexamethasone Ixazomib Lenalidomide Placebo
Updated 17 times since 2017 Last updated: Jul 20, 2023 Started: Apr 29, 2013 Primary completion: Dec 2, 2019 Completion: Jun 24, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Millennium Pharmaceuticals, Inc. and has accumulated 17 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Jan 2020 · 8 months · monthly snapshot~Jan 2020 – ~Nov 2020 · 10 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2022 · 13 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Aug 2023 · 9 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Nov 2022 — Aug 2023 [monthly]

    Completed PHASE3

▶ Show 12 earlier versions

  1. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Apr 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  8. May 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  10. Jun 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Millennium Pharmaceuticals, Inc.
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Amiens, France , Anaheim, United States , Angers, France , Ann Arbor, United States , Atlanta, United States , Auckland, New Zealand , Austin, United States , Baltimore, United States , Bayonne, France and 136 more locations